E-drug: NEW: Therapeutics Letter 37 now on the web
---------------------------------------------
I would like to bring to your attention the September / October 2000 issue
(#37) of the Therapeutics Letter on Antiplatelet Chemoprevention of
Occlusive Vascular Events and Death that was just made available a few
minutes ago on the Therapeutics Initiative web-site at
http://www.ti.ubc.ca/pages/letter37.htm
In this review, we summarize the benefit and harm from taking four
common antiplatelet drugs: acetylsalicylic acid, (Aspirin�,
etc.),ticlopidine (Ticlid�), clopidogrel (Plavix�) and dipyridamole
(Aggrenox�).
I invite you to drop by and have a look at this Letter. Please feel free to
forward this message to any of your friends or colleagues that might be
interested in this topic.
We would appreciate receiving your comments on this Therapeutics
Letter and its possible implications in clinical practice.
Best regards,
Ciprian D Jauca
Program Coordinator
Therapeutics Initiative - Evidence Based Drug Therapy
University of British Columbia
2176 Health Sciences Mall
Vancouver, BC V6T 1Z3
Canada
E-mail: jauca@ti.ubc.ca
Phone: +1 (604) 822-0700
GSM Mobile Phone: +1 (604) 722-2075
Fax: +1 (604) 822-0701
Web: http://www.ti.ubc.ca
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.